SCHEMBL131703

SCHEMBL131703

O[CH]c1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16951940 0.79 L3MBTL1 (0.50)
SCHEMBL10287939 0.79 ALDH1A1 (0.52)
SCHEMBL28861335 0.77 ALDH1A1 (0.86)
Bromide SCHEMBL8039510 0.77 ALDH1A1 (0.50)
SCHEMBL1058814 0.77 ALDH1A1 (0.62)
SCHEMBL3301954 0.77 ALDH1A1 (0.62)
SCHEMBL9586694 0.77 ALDH1A1 (0.62)
SCHEMBL16953070 0.75 ALDH1A1 (0.38)
SCHEMBL16955594 0.75 ALDH1A1 (0.46)
SCHEMBL16960255 0.75 TSHR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999740-B2 Fused pyrazine derivatives as A2A / A2B inhibitors INCYTE CORPORATION (US) 2024-06-04 US claimed
US-20220135570-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2022-05-05 US claimed
EP-3818063-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS Incyte Corporation (US) 2021-05-12 EP claimed
US-20200031835-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2020-01-30 US claimed
CN-102482731-B Method for recovering metals from aqueous solutions CYTEC TECH CORP 2015-06-10 CN claimed
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US claimed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US claimed
CN-102256944-A Sphingosine-1-phosphate receptor antagonists EXELIXIS INC 2011-11-23 CN claimed
CN-101903317-A Improved process for the preparation of 2- (substituted phenyl) -2 hydroxy-ethylcarbamates JANSSEN PHARMACEUTICA NV 2010-12-01 CN claimed
US-11999740-B2 Fused pyrazine derivatives as A2A / A2B inhibitors INCYTE CORPORATION (US) 2024-06-04 US disclosed
US-20220135570-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2022-05-05 US disclosed
US-11161850-B2 Fused pyrazine derivatives as A2A / A2B inhibitors INCYTE CORPORATION (US) 2021-11-02 US disclosed
EP-3818063-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS Incyte Corporation (US) 2021-05-12 EP disclosed
US-20200031835-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2020-01-30 US disclosed
US-4610861-A COBALT, PHOSPHINIC ACID AS EXTRACTANT INCO LIMITED (CA) 1986-09-09 US disclosed
US-4382016-A ORGANIC PHOSPHINIC ACID AMERICAN CYANAMID COMPANY (US) 1983-05-03 US disclosed
US-4353883-A Selective extraction of cobalt(II) from aqueous solutions with phosphinic acid extractants AMERICAN CYANAMID COMPANY (US) 1982-10-12 US disclosed
US-4348367-A Selective removal of cobalt(II) from aqueous solutions with phosphinic extractants AMERICAN CYANAMID COMPANY (US) 1982-09-07 US disclosed
EP-0046940-A2 Extraction process for the selective removal of cobalt (II) from aqueous solutions CYANAMID CANADA INC. (CA) 1982-03-10 EP disclosed
EP-0046933-A2 Extraction process for the selective removal of cobalt (II) from aqueous solutions CYANAMID CANADA INC. (CA) 1982-03-10 EP disclosed